StockTipsArenaBeta

BUY AstraZeneca Pharma India Ltd. — Kunal Saraogi

BUYAstraZeneca Pharma India Ltd.
AstraZeneca Pharma India share price target & all analyst calls

byKunal SaraogiHorizon: 1 year6 Nov 2026via Zee Business (Live)

Entry₹6,544Inferred
Target₹8,800
Total upside +34.47%
Stop lossNot given
CMP₹6,373.51d ago
Active-2.61%+38.07%upside left 12 mo left
Follow Kunal Saraogi for new callsGet alertsWatch ASTRAZEN for new buy/sell callsGet alertsSee 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST
7 supporting2 neutral3 opposing
Supports the BUY call (7)

AstraZeneca Pharma Q2 Results: Net profit up 15% on growth across key therapy areas

NewsCnbc-Tv18·5 Nov · yesterday

(opens in new tab)

AstraZeneca Pharma India reported a 30% growth in Q2 FY26-27, with total revenue from operations reaching INR 7,291 million, supported by strong performance across oncology, biopharmaceuticals, and ra

BSE · Company Update·5 Nov · yesterday

(opens in new tab)

AstraZeneca Pharma India reported unaudited financial results for the quarter ended September 30, 2026, showing a profit after tax of Rs 623.3 million compared to Rs 542.2 million in the same quarter

BSE · Board Meeting·5 Nov · yesterday

(opens in new tab)

The Delhi High Court has granted interim relief to the company, directing the NPPA to take no coercive steps to recover an alleged overcharging demand of approximately Rs 151.2 crore until the next he

BSE · Company Update·2 Nov · 5d ago

(opens in new tab)
Neutral / worth noting (2)

Nothing found in this tip’s window yet.

Weighs against the BUY call (3)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·6 Nov · yesterday

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on AstraZeneca Pharma India

All analyst calls on AstraZeneca Pharma India

More from Kunal Saraogi

Every call and its outcome